Tadalafil Protocol: ED, BPH, and Off-Label Endurance Use

Quick answer

Three protocol patterns are reported in the published tadalafil literature: on-demand for ED (10 or 20 mg before activity, 36-hour window), daily-dose for BPH/LUTS (5 mg every morning, steady-state at day 5, IPSS measured at week 4), and off-label daily-dose for endurance (2.5 to 5 mg daily, evidence limited and equivocal). Each protocol has a specific evidence base, outcome metric, and reassessment cadence. The HowTo schema on this page reflects the standard 30-day BPH/LUTS daily-dose pattern; the on-demand and off-label patterns are described in their respective sections below.

Table of contents

1. The 3 published protocols
2. ED on-demand protocol
3. BPH/LUTS daily-dose protocol
4. Off-label endurance protocol
5. Post-prostatectomy penile rehabilitation context
6. Verification checkpoints
7. When to reassess or switch
8. Frequently asked questions
9. References

---

The 3 published protocols

The tadalafil evidence base supports three operational protocol patterns. Each rests on a distinct body of clinical literature and uses a distinct outcome metric.

Protocol	Dose	Timing	Outcome metric	Evidence depth
ED on-demand	10 or 20 mg	30 min to 2 h pre-activity	IIEF, SEP-2, SEP-3	Extensive (head-to-head + multi-center RCTs)
BPH/LUTS daily	5 mg	Same time each day	IPSS, BII, IPSS-QoL	Extensive (12-trial pooled safety analysis)
Off-label endurance	2.5 to 5 mg daily	Same time each day	VO2max, time-to-exhaustion	Limited and equivocal

The decision among the three is driven by what question the research is asking. A study of acute peak-effect pharmacodynamics is best served by the on-demand protocol because exposure is concentrated. A study of long-term endothelial function or pulmonary hemodynamics is best served by the daily-dose protocol because exposure is steady-state. The off-label endurance protocol is appropriate only where the research question is specifically about hypoxic exercise tolerance and the researcher accepts the limited evidence base.

The HowTo schema on this page documents the standard 30-day BPH/LUTS daily-dose pattern. The on-demand and off-label patterns are described in the next two sections.

ED on-demand protocol

The on-demand protocol is the original tadalafil indication and the most-prescribed pattern in clinical practice. It is also the most-studied pattern in head-to-head comparison trials with sildenafil and vardenafil.

Dosing. A single 10 mg or 20 mg tablet taken approximately 30 minutes to 2 hours before anticipated activity. The 10 mg dose is the typical starting point in published protocols; titration to 20 mg is reserved for inadequate response or for researchers who tolerate the 10 mg dose without adverse events.

Timing. Tadalafil’s onset is approximately 1 to 2 hours after dosing, slower than sildenafil (30 to 60 minutes) and vardenafil (30 to 60 minutes). The trade-off is the 36-hour effective window: a single tadalafil dose covers most plausible activity timing without re-dosing. According to PubMed, this 36-hour window is the basis for the colloquial “weekend pill” framing in clinical literature (Porst et al., 2009, PMID 19756466, DOI).

Frequency. No more than one dose per 24 hours in published protocols. The 17.5-hour half-life means a second dose within 24 hours produces a higher cumulative AUC than the dose-by-dose pattern would suggest, with disproportionate side-effect burden.

Outcome metrics. The standard ED outcome metrics are the International Index of Erectile Function-5 (IIEF-5), the Sexual Encounter Profile question 2 (SEP-2: ability to penetrate), and SEP-3 (ability to maintain erection through completion). According to PubMed, a randomized phase II trial in patients with post-radiotherapy ED demonstrated significant improvements in all IIEF domains in both 20 mg on-demand and 5 mg once-daily arms after 12 weeks (Ricardi et al., 2010, PMID 21711479, DOI).

Cautions. The on-demand protocol’s pharmacokinetic profile means a single dose is still measurably present 48 hours later. Researchers in the on-demand pattern should observe the same 48-hour washout window before nitrate co-administration that the daily-dose pattern requires. The window is dose-independent.

BPH/LUTS daily-dose protocol

The 5 mg once-daily protocol is the most-studied tadalafil regimen and the basis for the regulatory-approved BPH/LUTS indication.

Dosing. 5 mg once daily, taken at approximately the same time each day. Morning dosing is the most common pattern in published trials. Steady-state plasma concentration is reached in approximately 5 days (7 elimination half-lives by the standard pharmacokinetic rule of thumb).

Outcome metrics. The International Prostate Symptom Score (IPSS) is the standard primary endpoint. The Benign Prostatic Hyperplasia Impact Index (BII) and IPSS quality-of-life subscores are common secondary endpoints. According to PubMed, dose-ranging and confirmatory studies that supported regulatory approval demonstrated 12 weeks of once-daily tadalafil 5 mg producing statistically significant improvements in total IPSS, BII, IPSS subscores, IPSS quality-of-life, and the IIEF, regardless of patient age, prior alpha-blocker exposure, baseline LUTS severity, or coexisting ED status (Carson et al., 2014, PMID 24341303, DOI).

Combination protocols. Tadalafil daily-dose can be combined with a 5-alpha reductase inhibitor (finasteride) for BPH/LUTS in patients with prostate volume greater than 40 mL. According to PubMed, a 2024 randomized trial compared tamsulosin/finasteride against tadalafil/finasteride for 12 weeks in BPH patients. Both combinations produced significant IPSS improvements. The tamsulosin combination produced better average flow rates at week 4. The tadalafil combination produced significant improvements in IIEF erectile function scores, while the tamsulosin combination significantly reduced IIEF scores across all domains (Tawfik et al., 2024, PMID 38308714, DOI).

Long-term safety. The 5 mg daily dose has the broadest published safety pool of any tadalafil regimen. According to PubMed, an integrated analysis of 12 phase II and phase III randomized double-blind placebo-controlled trials evaluated 5 mg once-daily tadalafil in men with LUTS/BPH, including a sub-population aged 75 years and older. No clinically relevant differences in long-term tolerability were observed between younger and older men, and there was no signal of increased cardiovascular adverse events (Oelke et al., 2017, PMID 27988986, DOI).

Reassessment cadence. IPSS at baseline, week 4, and week 12 is the published reassessment pattern. If IPSS improvement is at least 4 points and the patient is tolerating the regimen, continuation past 12 weeks is supported by the long-term safety data. If improvement is less than 4 points at week 12, the protocol should be reassessed: either uptitrate (off-label, research only), switch to combination therapy, or discontinue.

Off-label endurance protocol

The off-label endurance protocol is a tadalafil use case that extends from the Adcirca pulmonary arterial hypertension indication. The mechanistic rationale is that PDE5 inhibition produces smooth-muscle relaxation in the pulmonary vasculature, which can improve hypoxic ventilation-perfusion matching and theoretically increase exercise tolerance at altitude or in hypoxic conditions.

Dosing. Off-label endurance protocols typically use 2.5 to 5 mg daily, taken at the same time each day. The dose mirrors the BPH/LUTS regimen rather than the higher-dose Adcirca pulmonary hypertension regimen (40 mg daily for PAH).

Evidence base. This is the protocol with the thinnest published support. Some studies have reported improvements in VO2max or time-to-exhaustion at altitude or under hypoxic conditions; others have reported no significant effect. The literature is heterogeneous in outcome measure, study population (athletes vs untrained subjects, sea-level vs altitude), and dose. As a research protocol, it is appropriate where the research question is specifically about hypoxic exercise pharmacology. As a recreational performance enhancement, the evidence is too weak to support specific claims.

Frame. This page documents the protocol because it appears in the published research base, not because Elite Bio Supply makes any performance claim. Tadalafil distributed by Elite Bio Supply is for research use only.

Post-prostatectomy penile rehabilitation context

A specific research-protocol context for the daily-dose pattern is post-prostatectomy penile rehabilitation. According to PubMed, a 2024 retrospective analysis of 581 patients who underwent radical prostatectomy for prostate cancer evaluated a multi-modal penile rehabilitation regimen that included daily tadalafil, L-citrulline, and weekly vacuum erectile device, with the option of intracavernosal injections for non-responders. The incidence of Peyronie’s disease in this cohort was 2.9 percent, lower than the historical post-prostatectomy incidence of 15.9 percent in the general population. The authors note that prospective multi-institutional trials are needed to confirm whether penile rehabilitation prevents Peyronie’s disease (Kianian et al., 2024, PMID 38106686, DOI).

This protocol is research-context evidence for the long-term safety and tolerability of daily tadalafil in a specific population, and it illustrates how tadalafil’s daily-dose pattern integrates into multi-modal research designs.

Verification checkpoints

For any tadalafil protocol, three categories of verification checkpoint are appropriate:

Efficacy metrics. Use the validated instrument that matches the protocol’s research question. IPSS for BPH/LUTS, IIEF-5 for ED, VO2max or 6-minute walk test for endurance research. Baseline measurement before protocol initiation, week 4 mid-point, and week 12 final assessment is the published pattern.

Cardiovascular safety. Baseline blood pressure (sitting and standing) and resting heart rate before initiation. Re-measure at week 1, week 4, and week 12. Tadalafil’s expected hemodynamic effect is mild (systolic BP reduction of 3 to 5 mmHg). Larger drops, particularly with orthostatic symptoms, warrant reassessment.

Adverse event tracking. Daily symptom log for the first 14 days (the period when first-week side effects are most likely), then weekly through week 12. Specific symptoms to track: headache severity, back pain or myalgia, flushing, dyspepsia, vision changes, hearing changes, prolonged erection. Vision and hearing changes warrant immediate discontinuation and clinical evaluation.

When to reassess or switch

Inadequate response. For ED protocols, if IIEF-5 has not improved by at least 4 points after 12 weeks at the targeted dose, reassessment is warranted. Options include titrating up (10 mg to 20 mg on-demand), switching to a different PDE5 inhibitor (sildenafil 100 mg has the highest published response rate in the class), or transitioning to a combined regimen. For BPH/LUTS protocols, if IPSS has not improved by at least 4 points after 12 weeks at 5 mg daily, options include adding an alpha-blocker, adding a 5-alpha reductase inhibitor, or transitioning to a combination regimen.

Side-effect burden. If headache, back pain, or other adverse events are dose-limiting at the targeted dose, step down before discontinuing. Daily 5 mg can step down to 2.5 mg; on-demand 20 mg can step down to 10 mg. If side effects persist at the lowest dose, the appropriate decision is discontinuation rather than further reduction.

Pattern switch. A researcher who started on-demand and finds the timing inflexible can switch to daily-dose without a washout (the molecule is the same; only the dosing frequency changes). A daily-protocol researcher who experiences cumulative side effects can switch to on-demand after a 3 to 4 day washout.

Frequently asked questions

What’s the difference between daily and on-demand?
Daily-dose maintains continuous plasma concentration; on-demand creates a 36-hour activity window. Daily is preferred when timing is unpredictable; on-demand when preserving spontaneity matters less than minimizing dose burden.

How long until steady-state?
Approximately 5 days at the prescribed daily dose. This is roughly 7 elimination half-lives, the standard pharmacokinetic rule of thumb.

When should bloodwork or measurements happen?
If used for BPH/LUTS research, IPSS at week 4 is the standard checkpoint. For cardiovascular safety, baseline blood pressure and resting heart rate should be measured before and during the protocol.

Can the protocol be cycled on/off?
Tadalafil washout is approximately 3.5 days (5 half-lives). Cycling on/off is feasible but PDE5 inhibitor research generally favors continuous protocols for the daily-dose pattern.

What’s the off-label endurance protocol?
Some research has explored low-dose daily tadalafil (2.5 to 5 mg) for hypoxic exercise tolerance via pulmonary vascular relaxation. This is off-label and based on the Adcirca pulmonary hypertension indication. Endurance research evidence is limited and equivocal.

References

References sourced via PubMed.

---

Research use only. Not medical advice. Tadalafil is Schedule F in Canada.

Related reading

• Tadalafil pillar guide
• Tadalafil dosage guide
• Tadalafil side effects
• Tadalafil vs sildenafil